Where the signs are not inherently likely to distinguish the products or services in question, Member States may require, as an additional condition of registration as a trademark, that the distinctiveness has been acquired through use. Members are free to decide whether to allow the recording of signs that are not visually noticeable (. B for example, sound or olfactory traces). 3. Article 6 bis of the Paris Convention (1967) applies mutatis mutandis to products or services that are not comparable to those for which a trademark is registered, provided that the use of that trademark, with respect to those products or services, indicates a link between these products or services and the registered trademark holder, and where the interests of the registered trademark holder could be affected by such use. It is also customary for countries in the tobacco industry, which is the head of TRIPS, to be threatened with litigation. In general, tobacco companies will argue that a measure prevents them from using their trademarks or, in general, cannot adequately protect their brands. TRIPS arguments will often also appear in domestic or investment law, coupled with arguments about expropriation or other private property protections. Members may set the conditions for licensing and trademark transfers, in that it is not permitted to lay off trademarks and the registered trademark holder has the right to cede the trademark with or without transfer of the company to which the trademark belongs. Unlike other IP agreements, TRIPS have an effective enforcement mechanism. States can be disciplined by the WTO dispute settlement mechanism. Members can make the recording capacity of the use dependent.
However, the actual use of a trademark cannot be considered a precondition for filing a registration application and, after that filing date, it must be at least three years before non-compliance with an intention to use is allowed as a reason for rejecting the application (Article 14.3). Trips-plus conditions, which impose standards beyond TRIPS, have also been verified.  These free trade agreements contain conditions that limit the ability of governments to introduce competition for generic drug manufacturers. In particular, the United States has been criticized for promoting protection far beyond the standards prescribed by the TRIPS. The U.S. free trade agreements with Australia, Morocco and Bahrain have expanded patentability by making patents available for new uses of known products.  The TRIPS agreement authorizes the granting of compulsory licences at the discretion of a country. The terms of trips plus in the U.S. Free Trade Agreement with Australia, Jordan, Singapore and Vietnam have limited the application of mandatory licences to emergencies, remedies for cartels and abuse of dominance, and cases of non-commercial public use.
 In particular, TRIPS does not provide for any obligation to authorize the use of the mark (for example. B by advertising or advertising) or granting rights to the trademark holder to prevent the state from regulating the use of a trademark (for example. B by limiting these ads/advertisements). Trademarks are so-called negative rights, rights that prevent third parties from doing something.